Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542590 · ClinicalTrials.gov registry record
Natural History of Patients With PH3 and a History of Stone Events
A clinical trial, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- Completed
- Registry status
- 7
- Enrollment target
NCT04542590: Completed study, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
NCT04542590 is a clinical trial that has completed, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04542590 has completed, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence of pre existing stones detected by renal ultrasound at screening.
Primary Outcome
Collect data on the rate of new stone formation in PH3 patients of at least 2 years of age
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2024-07-23 |
What the finished NCT04542590 record still lists
NCT04542590 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04542590 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04542590 about?
NCT04542590 is a clinical study titled "Natural History of Patients With PH3 and a History of Stone Events". This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence of pre existing stones detected by renal ultrasound at screening.
What is the current status of trial NCT04542590?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2021-09-09. Estimated completion is 2024-07-23.
Who is sponsoring clinical trial NCT04542590?
This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI